#USA #Gates Foundation #Durham #Ten63 Therapeutics #BEYOND platform

Ten63 Therapeutics Secures Strategic Funding

Ten63 Therapeutics, an innovative company specializing in artificial intelligence for drug discovery, recently announced a successful financing round that has elevated its total funding to over $45 million. This new financial influx includes investments from notable institutions such as Chugai Venture Fund and the Gates Foundation, showcasing the growing confidence in the potential of AI in transforming medicine.

The standout feature of Ten63’s approach is its BEYOND platform, an AI-driven drug discovery system designed to simulate trillions of potential drugs, delivering accuracy that rivals traditional laboratory methods. As John Gustofson, President of Chugai Venture Fund remarked, the advanced technology not only accelerates the drug discovery process but also aims to tackle targets considered impossible for previous methodologies.

Advancing Drug Discovery

The additional funding is set to enhance the BEYOND platform, which has established itself as the world’s first Large Quantum Chemistry Model (LQCM). This remarkable technology allows for rapid and precise simulations, thereby enabling researchers to target the 80% of human proteins previously classified as undruggable. Ten63 is already making strides in areas that have stumped scientists for decades, particularly focusing on Myc, a notoriously challenging oncogene tied to a majority of cancer cases.

Dr. Marcel Frenkel, CEO of Ten63 Therapeutics, highlighted the significance of the platform: "AI not only accelerates drug discovery; it enables us to pursue high-impact targets in ways that were previously impossible." This resets the limitations that conventional experimental approaches have faced, especially in targeting data-poor and challenging areas.

Addressing Global Health Issues

Part of the strategic vision behind the newly acquired funds includes addressing the human papillomavirus (HPV) pandemic. The Gates Foundation’s engagement in the financing round is particularly aligned with this mission. HPV, a leading cause of various cancers, including cervical cancer, affects hundreds of thousands each year. Ten63 is at the forefront, utilizing its BEYOND platform to discover affordable and effective treatments targeting the viral proteins associated with these cancers.

Frenkel expressed confidence in their progress, noting that with their simulations, they can navigate through molecular possibilities faster than traditional methods, creating a pathway to breakthroughs in drug development.

Strong Support Network

The recent funding has attracted a broad coalition of investors, which now includes respected names like RYSE, K5 Global, SF Holdings, Duke Capital Partners, and Black Opal Ventures. The strategic guidance from these new investors, particularly with Mike Dial from Chugai Venture Fund joining the board, will support Ten63’s ambitious plans.

Board Chairman Clay Thorp emphasized the validation the funding provides, stating, "Ten63's approach has the potential to transform not just cancer treatment, but the entire spectrum of drug discovery." With the determined effort from Ten63, many once undruggable targets may soon see therapeutic solutions that could significantly impact patient care.

Conclusion

As Ten63 Therapeutics continues to push boundaries in drug discovery through its groundbreaking BEYOND platform, the implications for medicine are profound. With a blend of advanced computational abilities and strategic collaborations, Ten63 is not just enhancing the speed of drug discovery but is poised to truly revolutionize the landscape of therapeutic development, potentially leaving no target behind. To learn more about Ten63 and their initiatives, visit their official website.